IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	€0.1515	-0.98%	101
16/07/26	€0.1530	+0.33%	5,264
15/07/26	€0.1525	+4.10%	13,978
14/07/26	€0.1465	-2.66%	741
13/07/26	€0.1505	-1.31%	3,301

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 16:55:00 17/07/2026 BST			5-day change	1st Jan Change
0.1515 ^EUR	-0.98%		-0.66%	+13.91%

06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership

Market Cap	881K 1.01M 813K 749K 1.41M 97.03M 1.44M 9.71M 3.82M 47.52M 3.78M 3.7M 164M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.55M -2.06M -1.9M -3.57M -246M -3.65M -24.58M -9.67M -120M -9.58M -9.37M -414M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership
04-24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
04-23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/10/25	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/07/25	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
29/04/25	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/01/25	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
18/10/24	IntegraGen: losses reduced, share price soars
29/07/24	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/07/24	IntegraGen Reports Sales Results for the First-Half of 2024	CI
01/05/24	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
29/04/25	IntegraGen: 2024 Annual Results	BU
15/01/25	IntegraGen : Inside Information / Information on annual revenues	PU
15/01/25	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

IntegraGen Share Price

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news : IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Course Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

06-16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime
06-16	IntegraGen en procédure de redressement judiciaire
06-16	Le marché remet sa cape d'invincibilité
06-16	IntegraGen convertit sa procédure de sauvegarde en redressement judiciaire
06-15	IntegraGen annonce la conversion de sa procédure de sauvegarde en redressement judiciaire afin de poursuivre les discussions engagées avec des acteurs intéressés par ses activités

1 day	-0.98%
1 week	-0.66%
Current month	-11.92%
1 month	-22.31%
3 months	-5.31%
6 months	+12.22%
Current year	+13.91%

1 week	0.15	0.15
1 month	0.15	0.19
Current year	0.12	0.36
1 year	0.12	0.37
3 years	0.12	1.5
5 years	0.12	2.04
10 years	0.12	4.29

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	08/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	31/12/2022
Berengere Genin COO	Chief Operating Officer	-	31/12/2023

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	21/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	31/12/2020
François Blondel BRD	Director/Board Member	62	30/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	-0.98%	-0.66%	-36.61%	-89.76%	1.15M
VERACYTE, INC.	-0.15%	+3.79%	+144.14%	+97.63%	4.73B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.71%	+8.83%	+118.29%	+210.99%	3.54B
BGI GENOMICS CO., LTD.	-5.50%	-0.75%	-29.85%	-37.41%	2.15B
CAREDX, INC.	-1.51%	+39.35%	+236.41%	+292.59%	2.08B
IOVANCE BIOTHERAPEUTICS, INC.	+7.30%	+18.20%	+113.68%	-37.66%	2.08B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.12%	+18.88%	+188.45%	-42.17%	1.05B
SEEGENE, INC.	-2.39%	-1.55%	-12.29%	+35.95%	878M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-4.16%	+6.17%	-33.94%	-12.03%	535M
CURIOX BIOSYSTEMS CO., LTD	-3.06%	-3.18%	-2.02%	-	478M
Average	-0.46%	+9.04%	+68.62%	+46.46%	1.75B
Weighted average by Cap.	+0.52%	+10.65%	+110.24%	+96.19%

	2019	2020
Net sales	8.28M 9.47M 7.64M 7.04M 13.27M 912M 13.57M 91.32M 35.92M 447M 35.58M 34.8M 1.54B	9M 10.3M 8.3M 7.66M 14.43M 992M 14.75M 99.27M 39.04M 486M 38.68M 37.83M 1.67B
Net income	-285K -326K -263K -242K -457K -31.39M -467K -3.14M -1.24M -15.37M -1.22M -1.2M -52.92M	-375K -429K -346K -319K -601K -41.32M -615K -4.14M -1.63M -20.24M -1.61M -1.58M -69.67M
Net Debt	-2.52M -2.88M -2.32M -2.14M -4.04M -278M -4.13M -27.78M -10.93M -136M -10.82M -10.59M -468M	-3.11M -3.56M -2.87M -2.64M -4.98M -343M -5.09M -34.29M -13.49M -168M -13.36M -13.07M -578M